Uterus globulin associated protein 1 (UGRP1) binds podoplanin (PDPN) to promote a novel inflammation pathway during Streptococcus pneumoniae infection

Lei Han¹ | Feifei Zhang² | Yu Liu³ | Jie Yu¹ | Qianyue Zhang¹ | Xiaoping Ye¹ | Huaidong Song¹ | Cuixia Zheng³ | Bing Han⁴

¹The Core Laboratory in Medical Center of Clinical Research, Department of Molecular Diagnostics and Endocrinology, Shanghai Ninth People’s Hospital, State Key Laboratory of Medical Genomics, Shanghai Jiao Tong University School of Medicine, Shanghai, China
²Department of Ophthalmology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
³Department of Respiration, Yangpu Hospital, Tongji University School of Medicine, Shanghai, China
⁴Department of Endocrinology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Correspondence
Huaidong Song, The Core Laboratory in Medical Center of Clinical Research, Department of Molecular Diagnostics and Endocrinology, Shanghai Ninth People’s Hospital, State Key Laboratory of Medical Genomics, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China. Email: huaidong_s1966@163.com

Cuixia Zheng, Department of Respiration, Yangpu Hospital, Tongji University School of Medicine, Shanghai, China. Email: zcx9566@163.com
1. UGRP1–PDPN signalling activate RhoA to enhance the interaction of IKKγ and IKKβ.
2. Interaction of IKKγ and IKKβ activate NF-κB to enhance expression of TLR2, MyD88 and NOD2.
3. Upon *S. pneumoniae* infection, increased expression of TLR2, MyD88 and NOD2 could generate enhanced NF-κB signalling to produce more pro-inflammatory cytokines including IL-6, IL-1β and TNFα.
Uterus globulin associated protein 1 (UGRP1) binds podoplanin (PDPN) to promote a novel inflammation pathway during Streptococcus pneumoniae infection

Lei Han1 | Feifei Zhang2 | Yu Liu3 | Jie Yu1 | Qianyue Zhang1 | Xiaoping Ye1 | Huaidong Song1 | Cuixia Zheng3 | Bing Han4

1The Core Laboratory in Medical Center of Clinical Research, Department of Molecular Diagnostics and Endocrinology, Shanghai Ninth People’s Hospital, State Key Laboratory of Medical Genomics, Shanghai Jiao Tong University School of Medicine, Shanghai, China
2Department of Ophthalmology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
3Department of Respiration, Yangpu Hospital, Tongji University School of Medicine, Shanghai, China
4Department of Endocrinology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Correspondence
Huaidong Song, The Core Laboratory in Medical Center of Clinical Research, Department of Molecular Diagnostics and Endocrinology, Shanghai Ninth People’s Hospital, State Key Laboratory of Medical Genomics, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China.
Email: huaidong_s1966@163.com

Cuixia Zheng, Department of Respiration, Yangpu Hospital, Tongji University School of Medicine, Shanghai, China.
Email: zcx9566@163.com

Bing Han, Department of Endocrinology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China.
Email: foxhb1423@126.com

Lei Han, Feifei Zhang, Yu Liu and Jie Yu contributed equally.

Funding information
National Natural Science Foundation, Grant/Award Numbers: 81800749.

Abstract
Background: Streptococcus pneumoniae is the major cause of life-threatening infections. Toll-like receptors (TLRs) and NOD-like receptors (NLRs) could recognise S. pneumoniae and regulate the production of pro-inflammatory cytokines. UGRP1, highly expressed in lung, is predominantly secreted in airways. However, the function of UGRP1 in pneumonia is mainly unknown.

Methods and results: We showed that upon TLR2/TLR4/NOD2 agonists stimulation or S. pneumoniae infection, treatment with UGRP1 could promote phosphorylation of p65 and enhance IL-6, IL-1β and TNFα production in macrophages. We further elucidated that after binding with cell-surface receptor PDPN, UGRP1 could activate RhoA to enhance interaction of IKKγ and IKKβ, which slightly activated NF-κB to improve expression of TLR2, MyD88, NOD2 and NLRP3. Deletion of UGRP1 or blocking UGRP1 interaction with PDPN protected mice against S. pneumoniae-induced severe pneumococcal pneumonia, and activating RhoA with agonist in UGRP1-deficient mice restored the reduced IL-6 production.

Conclusion: We demonstrated that UGRP1–PDPN–RhoA signaling could activate NF-κB to promote expression of TLR2, MyD88, NOD2 and NLRP3, which enhanced inflammatory cytokines secretion during S. pneumoniae infection. Antibodies, which could interrupt interaction of UGRP1 and PDPN, are potential therapeutics against S. pneumoniae.
INTRODUCTION

As a gram-positive bacterium, Streptococcus pneumoniae exists in and invades the respiratory tract. It is the major cause of community acquired pneumonia and results in about 90% pneumonia deaths, especially in young children and the elderly.\(^1,2\) So, it is an important cause of morbidity and mortality worldwide.\(^2\)

With pattern recognition receptors (PRRs) of the innate immune system, host could firstly recognised \(S.\) pneumoniae. Toll-like receptors (TLRs) and NOD-like receptors (NLRs) have been identified as different classes of PRRs. Bacterial virulence factors and conserved microbial molecules can activate these receptors.\(^3,4\) After activation, most PPRs stimulate the transcription factor NF-\(\kappa\)B to produce the pro-inflammatory cytokines, including IL-6, IL-1\(\beta\) and TNF\(\alpha\). Subsequently, these cytokines regulate the adaptive immunity by stimulating immune cells, activating the acute-phase response and recruiting neutrophils and macrophages.\(^5\)

The host could be protected from \(S.\) pneumoniae by balanced inflammation, while would be harmed by excessive inflammation induced by TLR and NLR signalling pathways extreme activation. The most dying patients with severe pneumococcal pneumonia are commonly caused by rigorous inflammation. Compared with other cytokines, IL-6 shows more inflammatory effect and correlates prominently with death rates in the patients with severe pneumococcal pneumonia.\(^6\)

Extracellular proteins have been reported to regulate TLR signalling pathway by more and more studies. It was reported that vascular endothelial growth factor C (VEGF-C) and its cell surface receptor VEGFR-3 could restrain TLR4-NF-\(\kappa\)B signalling and IL-6 expression.\(^7\) Tumor-secreted protein S (Pros1), a Mer/Tyro3 ligand, was also demonstrated to decrease IL-6 expression in LPS and IFNy-stimulated macrophages.\(^8\) Same as extracellular protein, deficiency of tissue inhibitor of metalloproteinases-3 results in increased IL-6 expression in LPS-induced macrophages.\(^9\)

Uterus globulin-associated protein 1 (UGRP1), with the other name of SCGB3A2, is an extracellular protein mainly secreted by lung cells. The epithelial cells of the bronchial tubes, bronchus and trachea have the high expression of UGRPI, while thyroid gland also expresses UGRPI lowly.\(^10\) It was reported that UGRPI was involved in pathogenesis of autoimmune thyroid disease (AITD) and enhanced expression of UGRPI was reported in thyroids of AITD patients.\(^11,12\) Chiba et al.\(^13\) showed that UGRPI can restrain inflammation in the mouse model of allergic airway inflammation. Other studies also showed UGRPI had anti-inflammatory property and recombinant human UGRPI could be used as an anti-inflammatory agent in allergic pulmonary inflammation.\(^14,15\) However, the function of UGRPI in inflammation is still controversial. It was reported that UGRPI could combine LPS and deliver LPS to the cytosol, which activate caspase-11 to induce maturation of IL-1\(\beta\) and pyroptosis of macrophages.\(^16,17\) Because of the relationship of UGRPI and inflammation described above, we intended to investigate the function of UGRPI in lung inflammation induced by \(S.\) pneumoniae.

In this study, we showed that UGRPI positively regulated IL-6, IL-1\(\beta\) and TNF\(\alpha\) production in \(S.\) pneumoniae-infected or TLR2/TLR4/NOD2 agonist-treated macrophages, which was dependent on the combination of UGRPI and cell-surface receptor PDPN (podoplanin). Furthermore, interaction of UGRPI and PDPN activates RhoA to enhance interaction of IKK\(\gamma\) and IKK\(\beta\), which slightly activates NF-\(\kappa\)B to increase expression of TLR2, MyD88, NOD2 and NLRP3. We found a novel inflammation pathway that enhanced NF-\(\kappa\)B phosphorylation in an TLR2/4 independent manner.

RESULTS

2.1 UGRPI was identified to positively regulate inflammation in \(S.\) pneumoniae stimulated macrophages

We first assessed UGRPI expression in different murine organs and cells. Then, we found UGRPI was highly expressed in lung and there was no UGRPI expression in spleen, liver, kidney, peripheral blood mononuclear cells (PBMCs), bone marrow-derived macrophages (BMDMs) and peritoneal exudate macrophages (PEMs) (Figure 1A
FIGURE 1  UGRP1 was identified to positively regulate inflammation in *S. pneumoniae* stimulated macrophages. (A) Immunoblot analysis of UGRP1 protein expression in murine lung, spleen, liver, kidney, PBMCs, BMDMs and PEMs. (B) PEMs were treated with BSA or UGRP1 (0.5 μg/ml) for 1 h followed by *S. pneumoniae* (10^4 CFU/well) infection for 6 h to check *Il6, Il1b* and *Tnfa* mRNA by qRT-PCR (*n* = 3). (C) RAW264.7 cells were treated with BSA or UGRP1 (0.5 μg/ml) for 1 h followed by Pam3CSK4 (0.5 μg/ml) stimulation for 6 or 9 h to check *Il6, Il1b* and *Tnfa* mRNA by qRT-PCR (*n* = 3). (D) PEMs were treated with BSA or UGRP1 (0.5 μg/ml) for 1 h followed by MDP (1 μg/ml) or LTA (0.5 μg/ml) stimulation for 6 h to check *Il6, Il1b* and *Tnfa* mRNA by qRT-PCR (*n* = 3). (E and F) PEMs (E, *n* = 3) or RAW264.7 cells...
and Figure S1A), which was identical to previous reports. To investigate whether UGRP1 participated in inflammation response after S. pneumoniae infection, we treated S. pneumoniae-stimulated PEMs with UGRP1 and found UGRP1 increased mRNA levels of Il6, Il1b and Tnfa (Figure 1B). Meanwhile, we also found UGRP1 slightly increased mRNA levels of Il6, Il1b and Tnfa in PEMs without infection of S. pneumoniae (Figure 1B). With the consideration that some components of S. pneumoniae could be recognised by TLRs and NLRs including TLR2, TLR4 and NOD2, which was also verified by gene silencing studies (Figure S1B,C), we stimulated macrophages with Pam3CSK4 (agonist of TLR2), LTA (agonist of TLR2), LPS (agonist of TLR4) or MDP (agonist of NOD2) with or without UGRP1. In Pam3CSK4 or LPS stimulated RAW264.7 cells (murine macrophage cell lines), UGRP1 enhanced mRNA levels of Il6 and Il1b in 6 and 9 h, simultaneously with enhanced Tnfa mRNA levels in 9 h (Figure 1C and Figure S1D). Consistently, with the stimulation of MDP or LTA, UGRP1 increased mRNA levels of Il6, Il1b and Tnfa in PEMs (Figure 1D). Also, in LPS stimulated PEMs and BMDMs, UGRP1 enhanced Il6, Il1b and Tnfa mRNA levels (Figure S1E,F). Then, we also confirmed UGRP1-mediated increased expression of IL-6 and TNFα by ELISA in Pam3CSK4, LTA, MDP, LPS or S. pneumoniae stimulated PEMs (Figure 1E and Figure S1G) and RAW 264.7 cells (Figure 1F and Figure S1H). In addition, we observed that UGRP1 could not enhance the anti-inflammatory cytokine Il10 mRNA in Pam3CSK4-stimulated PEMs, although slightly increased Il10 mRNA could be induced by UGRP1 alone (Figure S1I). Together, we have identified that the UGRP1 enhances TLR2/4 and NOD2-induced inflammation in macrophages.

2.2 UGRP1 enhances TLR2-induced NF-κB activation

As one of the main transcription factors activated by Pam3CSK4, NF-κB can induce the expression of inflammatory cytokines. Following phosphorylation and activation of IKKα/β, IκBα is phosphorylated and polyubiquitinated for subsequent degradation, resulting in nuclear entry of NF-κB. Therefore, we wonder whether or not UGRP1 could affect the NF-κB signalling pathway. Consistent with our former data, UGRP1-treated PEMs showed enhanced phosphorylation levels of p65 (subunit of NF-κB) and IKKα/β with increased degradation of IκBα following Pam3CSK4 stimulation (Figure 2A,B). Simultaneously, enhanced translocation of p65 into nucleus was also observed in UGRP1-treated PEMs (Figure 2C and Figure S2A). Interestingly, following UGRP1 treatment for 1 h without any other stimulation, PEMs showed slightly increased phosphorylation of p65 and IKKα/β and degradation of IκBα (Figure 2D). Furthermore, p65 phosphorylation and IκBα degradation after UGRP1 treatment were much weaker than those after Pam3CSK4 stimulation for 1 h (Figure S2B). These results were in accordance with slightly enhanced expression of Il6, Il1b and Tnfa in PEMs, BMDMs and RAW264.7 cells after UGRP1 treatment alone (Figure 1B–F and Figure S1D–H).

In order to better understand the function of UGRP1, we generated UGRP1 knockout (KO) mice with a recombinering-based method. 3.6 kbp genomic sequence including the whole Ugrp1 gene was replaced by 2.3 kbp DNA fragment containing Neomycin cassette (Figure S2C). The efficiency of UGRP1 KO in lungs was confirmed by western blotting (Figure S2D). Normal percentages of B220+, CD4+ and CD8+ lymphocytes, and F4/80+ CD11b+ macrophages in spleen were demonstrated in UGRP1 KO mice, while normal T cell development in the thymus were also showed in UGRP1 KO mice, which were bred in a specific-pathogen-free facility (Figure S2E). Bone marrow cells from UGRP1 KO mice were then induced with M-CSF, and the development of BMDMs were not affected, showed normal percentages of F4/80+ CD11b+ macrophages (AMs; Figure 2E), but unchanged in PEMs and BMDMs (Figure S2G,H) from UGRP1 KO mice after treated with Pam3CSK4 or S. pneumoniae, which would be explained by positive expression of UGRP1 in lung but negative expression of UGRP1 in PEMs, BMDMs and any other cells we tested (Figure 1A and Figure S1A). These results were in accordance with average 50–100 times of UGRP1’s concentration in BAL fluid than in serum, indicating that UGRP1 mainly play a role in lung. Then, during stimulation of Pam3CSK4, adding back UGRP1 protein restored the reduced Il6 and Tnfa mRNA levels in AMs derived from UGRP1-deficient mice (Figure S2I). To determine whether NF-κB is the central transcription factor downstream of UGRP1, we next blocked NF-κB activation by pyrimidine-dithiocarbamate (PDTC) treatment, which profoundly suppressed Il6 mRNA (F, n = 3) were treated with BSA or UGRP1 (0.5 μg/ml) for 1 h followed by Pam3CSK4 (0.5 μg/ml), LTA (0.5 μg/ml), MDP (1 μg/ml) stimulation or S. pneumoniae (10⁴ CFU/well) infection for 12 h to check IL-6 and TNFα concentrations by ELISA. *p < .05, **p < .01 and ***p < .001, using two-way analysis of variance (ANOVA) with Holm–Sidak’s multiple comparisons test (B–F). Data from at least three independent experiments (mean ± SD) or representative data (A). Please also see Figure S1.
FIGURE 2 UGRP1 enhances TLR2-induced NF-κB activation. (A–C) Immunoblot analysis of phosphorylated (p-) p65 (A), p-IKKα/β, degradation of IκBα (B) and p65 in the whole cell lysate (left) and nucleus (right) in BSA or UGRP1-treated PEMs for 6 h following Pam3CSK4 stimulation for the indicated periods. β-Actin and tubulin were used as the whole lysate protein control, Lamin-B served as the nucleic protein control. (D) Immunoblot analysis of p-IKKα/β, p-p65 and degradation of IκBα in PEMs with treatment of UGRP1 for the indicated periods. (E) Alveolar macrophages (AMs) from WT or UGRP1 KO mice were stimulated with Pam3CSK4 or S. pneumoniae for 6 h to check Il6, Il1b and Tnfa mRNA by qRT-PCR (n = 3). (F) PEMs were treated with the NF-κB inhibitor PDTC (100 μM) for 1 h followed by BSA or UGRP1 (0.5 μg/ml) treatment and Pam3CSK4 stimulation for 6 h to measure Il6 mRNA by qRT-PCR (n = 3). (G) PEMs were treated with the NF-κB inhibitor PDTC (100 μM) for 1 h followed by BSA or UGRP1 (0.5 μg/ml) treatment for 6 h, then stimulated by Pam3CSK4 for 0.5 h, p65 in the whole cell lysate (left) and nucleus (right) was analysed by immunoblot. Tubulin were used as the whole lysate protein control, Lamin-B served as the nucleic protein control. *p < .05, **p < .01 and ***p < .001, using two-way analysis of variance (ANOVA) with Holm–Sidak’s multiple comparisons test (E and F). Data from at least three independent experiments (mean ± SD) or representative data (A–D, G). Please also see Figure S2.
(Figure 2F) and nucleus translocated p65 (Figure 2G) to the similar levels in UGRP1-treated and -untreated PEMs followed by Pam3CSK4 stimulation. Collectively, we have demonstrated that UGRP1 enhances S. pneumoniae-induced NF-κB activation and pro-inflammatory cytokine production in macrophages.

2.3 UGRP1 enhances expression of TLR2, NOD2, MyD88 and NLRP3 by activation of NF-κB

In order to identify whether increased production of pro-inflammatory cytokine, which resulted from UGRP1 together with agonist stimulation, was dependent on synthesis of new protein. Protein synthesis inhibitor cycloheximide (CHX) was used to treat PEMs with UGRP1 and Pam3CSK4 stimulation. Similar *Il1b* mRNA levels were observed in CHX and Pam3CSK4 stimulated PEMs with or without UGRP1 treatment (Figure 3A), which implied that UGRP1 enhanced expression of pro-inflammatory cytokine was dependent on new protein synthesis. In order to identify the UGRP1-induced protein, we used mRNA sequencing analysis as well as qRT-PCR to check UGRP1-treated macrophages, and increased mRNA levels of *Tlr2*, *Myd88*, *Nod2* and *Nlrp3*, but not *Tlr4*, were observed (Figure 3B, C and Figure S3A). Immunoblot analysis also confirmed enhanced expression of TLR2, MyD88, NOD2 and NLRP3 total expression with FACS assay (Figure S3B).

In addition, UGRP1 treatment also increased expression of MyD88 in phorbol-12-myristate-13-acetate (PMA)-induced human THP-1 cells (Figure S3C).

In consideration of enhanced NF-κB activation induced by UGRP1, we used PDTC to incubate with PEMs followed by UGRP1 treatment. Reduced expression of TLR2, NOD2 and MyD88 was observed after PDTC treatment (Figure 3E and Figure S3D). The occupation of the *Tlr2* and *Nod2* promoter region by the NF-κB subunit p65 was detected in UGRP1-treated PEMs using chromatin immunoprecipitation (ChIP) assays (Figure 3F), which indicated that UGRP1 enhanced TLR2 and NOD2 expression by activation of NF-κB. In order to verify whether UGRP1 motivated the same signalling proteins as TLRs to activate NF-κB, MyD88 KO PEMs were treated with UGRP1 and increased TLR2 and NOD2 expression was still observed (Figure 3G and Figure S3E), although Pam3CSK4 stimulated MyD88 KO PEMs showed almost no *Il6* expression (Figure S3F). Then, various inhibitors of TLRs-NF-κB signalling kinases, including IRAK1/4 inhibitor (IRAK-1-4 Inhibitor I), TAK1 inhibitor (Takinib), IKKβ inhibitor (LY2409881 trihydrochloride) and p-IκBα (BAY 11–7082), were used to incubate with UGRP1-treated PEMs, and we observed reduced *Tlr2* and *Nod2* mRNA levels followed by inhibition of IKKβ and p-IκBα, while almost unchanged expression of *Tlr2* and *Nod2* after blocking activation of IRAK1/4 and TAK1 (Figure 3H). In addition, reduced *Il6* mRNA levels could be observed in Pam3CSK4 stimulated PEMs following any inhibitor treatment mentioned above (Figure S3G) and these inhibitors also had no effect on PEMs viability (Figure S4M). Since Pam3CSK4 could activate NF-κB, we demonstrated that Pam3CSK4 stimulation could enhance the expression of TLR2 which would be even more with UGRP1 treatment (Figure S3H). In accordance with PEMs data, AMs from UGRP1-deficient mice showed depressed expression of TLR2 (Figure S3I). Together, these data suggest that UGRP1 enhances expression of TLR2, NOD2 and MyD88 by activation of IKKβ and phosphorylation of IκBα.

2.4 UGRP1–PDPN signalling activates RhoA to regulate TLR2-induced inflammation

In order to understand the underline mechanism of NF-κB activation by UGRP1, we used mass spectrometry to search for the cell-surface receptor which could bind UGRP1 to transfer signals into the cells. Several receptors were identified including MARCO, syndecan-1 (SDC1) and PDPN which were also reported to combine with UGRP1. Then, we used specific small interfering RNA (siRNA) to silence *Marco*, *Sdc1* and *Pdpn* in primary PEMs (siRNA silencing efficiency shown in Figure S4A). Similar *Il6* expression was observed in *Pdpn*-silencing PEMs followed by Pam3CSK4 stimulation with or without UGRP1 treatment, while *Marco* or *Sdc1*-silencing PEMs still showed increased *Il6* expression after Pam3CSK4 and UGRP1 stimulation (Figure 4A and Figure S4B). Subsequently, we used two kinds of anti-PDPN antibodies named B-II and F-3 from Santa Cruz to block PDPN and observed decreased *Il6* expression compared with control IgG treatment in PEMs after UGRP1 and Pam3CSK4 stimulation (Figure 4B). After F-3 blocking, UGRP1 and Pam3CSK4 treatment enhanced *Il6* expression slightly compared with BSA control and Pam3CSK4 treatment, while B-II blocked PEMs showed similar *Il6* expression followed by Pam3CSK4 stimulation with or without UGRP1 (Figure 4B), suggesting better PDPN-blocking effect of B-II. On the other hand, both F-3 and B-II had no effect on PEMs viability (Figure S4C).
FIGURE 3  UGRP1 enhances expression of TLR2, NOD2, MyD88 and NLRP3 by activation of NF-κB. (A) PEMs were treated with the protein synthesis inhibitor CHX (10 μM) for 1 h followed by Pam3CSK4 stimulation with BSA or UGRP1 (0.5 μg/ml) for 6 h to measure Il1b mRNA by qRT-PCR (n = 3). (B) The relative mRNA levels of gene from TLRs and NLRs pathway in PEMs after UGRP1 (0.5 μg/ml) treatment for 3 h (n = 3). (C) PEMs were treated with UGRP1 (0.5 μg/ml) for 3 or 6 h to check Tlr2, Myd88, nod2 and Nlrp3 mRNA by qRT-PCR (n = 3). (D) PEMs were treated with UGRP1 (0.5 μg/ml) for the indicated periods to check NLRP3, TLR2, Myd88 and NOD2 protein levels by immunoblot analysis. (E) PEMs were treated with the NF-κB inhibitor PDTC (100 μM) for 1 h followed by BSA or UGRP1 (0.5 μg/ml) treatment for 6 h to measure Tlr2 and nod2 mRNA by qRT-PCR (n = 3). (F) PEMs were treated with UGRP1 (0.5 μg/ml) for 1 h and the relative amount of Tlr2 and nod2 DNA binding to p65 was analysed by ChIP assay. (G) MyD88 KO PEMs were treated with UGRP1 (0.5 μg/ml) for 6 h to check Tlr2 and nod2 mRNA by qRT-PCR (n = 3). (H) PEMs were treated with IRAK1/4 inhibitor IRAK-1-4 Inhibitor I (10 μM), TAK1 inhibitor Takinin (10 μM), IkkK2 inhibitor LY2409881 trihydrochloride (5 μM) or p-1xBz inhibitor BAY 11–7082 (20 μM) for 1 h.
The increased expression of TLR2 after UGRP1 treatment could also be restrained by B-II or F-3 blocking, with the better suppressing effect of B-II (Figure S4D). We then verified the interaction of FLAG-tagged UGRP1 and HA-tagged PDNP using immunoprecipitation in 293T cells (Figure 4C), and B-II could interrupt the interaction of UGRP1 and PDNP (Figure S4E). Moreover, purified GST-tagged UGRP1 could also pull down endogenous PDNP in PEMs (Figure 4D).

Then we generated PDNP-ablated RAW264.7 cell lines with the CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)/Cas9 system. The genetic ablation efficiency was tested (Figure S4F). UGRP1 treatment could not enhance Il6 expression in PDNP-deficient RAW264.7 cells after Pam3CSK4 stimulation (Figure 4E), and PDNP deficiency also suppressed enhanced translocation of p65 into nucleus (Figure S4G). Consistently, elimination of increased NLRP3, NOD2, TLR2 and MyD88 expression with constant expression of TLR4 was observed in UGRP1-treated PDNP-deficient RAW264.7 cells (Figure 4F,G), which showed diminished UGRP1 binding as well (Figure S4H). Then, PDNP was overexpressed in RAW264.7 cells (Figure S4I), and increased Il6 expression was observed in PDNP-overexpressed cells with UGRP1 and Pam3CSK4 stimulation (Figure 4H). Flow cytometry assay showed positive expression of PDNP in AMs (Figure S4J), indicating that like PEMs and RAW264.7 cells, UGRP1 could stimulate the same signalling pathway in AMs. So, we have demonstrated that UGRP1 interacts with PDNP, and this interaction could enhance the expression of TLR2, NOD2 and MyD88 to amplify NF-κB activation.

PDNP is a small transmembrane glycoprotein, which co-localises with members of the ERM (ezrin, radixin, moesin) protein family and triggers small GTPase RhoA activation. In order to identify whether UGRP1-induced enhancement of IL-6 expression was dependent on RhoA activation. RhoA inhibitor CCG-1423 was used and we observed similar IL-6 expression after Pam3CSK4 stimulation with UGRP1 or BSA control treatment (Figure 4I and Figure S4K). Since small GTPase proteins including Cdc42 and Rac1 were also reported to be regulated by PDNP, we used CASIN (Cdc42 inhibitor), 1A-116 (Rac1 inhibitor) or MBQ-167 (dual Cdc42/Rac1 inhibitor) to inhibit Cdc42 and Rac1 activation and still observed enhanced IL-6 expression in UGRP1-treated PEMs compared with BSA-treated controls after Pam3CSK4 stimulation (Figure 4J). Consistently, UGRP1-induced enhancement of p65 translocation into nucleus was suppressed by CCG-1423 after Pam3CSK4 stimulation (Figure 4J). Increased NLRP3, TLR2, MyD88 and NOD2 expression induced by UGRP1 alone was also restrained by CCG-1423, with no effect on expression of TLR4 (Figure 4K and Figure S4L). In addition, these inhibitors had no effect on PEMs viability (Figure S4M). Then, RhoA activator Narciscaline was used and we observed suppressed IL-6 expression, resulted from PDNP deficient, was recovered in Cas9-Pdpn RAW264.7 cells after UGRP1 and Pam3CSK4 treatment (Figure 4L). Meanwhile, increased expression of NLRP3, NOD2, TLR2 and MyD88, resulted by RhoA activation, was eliminated by NF-κB inhibition (Figure S4N). These results indicate that enhancement of NF-κB activation induced by UGRP1–PDNP signalling is dependent on RhoA activation.

2.5 | UGRP1 activates RhoA to enhance the interaction of IKKγ and IKKβ

We used GST-Rhotekin-RBD pull-down assay to test the activation of RhoA. UGRP1-treated PEMs showed increased RhoA activation (Figure 5A), which was also exhibited in UGRP1-treated Cas9-control RAW264.7 cells (Figure 5B), and PDNP deficiency restrained the enhancement of activated RhoA in UGRP1-treated RAW264.7 cells (Figure 5B). Since the activated RhoA was reported to enhance the interaction of IKKγ and IKKβ to result in IKKβ activation,26 we constructed the constitutively active RhoA mutant V14 (glycine in 14 was replaced by valine) and constitutively negative RhoA mutant N19 (threonine in 19 was replaced by asparagin). Then, vector control, RhoA, V14 or N19 was transfected into 293T cells with IKKγ and IKKβ. We observed increased combination of IKKγ and IKKβ in RhoA transfected cells compared with vector control transfected cells (Figure 5C). Constitutively active mutant V14 transfected cells showed most combination of IKKγ and IKKβ, and constitutively negative mutant N19 transfected cells exhibited similar combination of IKKγ and IKKβ compared with vector transfected controls (Figure 5C). In RAW264.7 cells, enhanced combination of IKKγ and IKKβ was observed after UGRP1 treatment, and PDNP deficiency or RhoA inhibitor CCG-1423 followed by UGRP1 (0.5 μg/ml) treatment for 6 h to measure Thr2 and Nod2 mRNA by qRT-PCR (n = 3). *p < .05, **p < .01 and ***p < .001, using a two-tailed, unpaired Student’s t-test (G), one-way analysis of variance (ANOVA) with Holm–Sidak’s multiple comparisons test (C and H) or two-way ANOVA with Holm–Sidak’s multiple comparisons test (A and E). Data from at least three independent experiments (mean ± SD) or representative data (D). Please also see Figure S3.
FIGURE 4 UGRP1–PDPN signalling activates RhoA to regulate TLR2-induced inflammation. (A) PEMs were transfected with control siRNA, Marco siRNA, Sdc1 siRNA or Pdpn siRNA followed by Pam3CSK4 (0.5 μg/ml) stimulation for 6 h with BSA or UGRP1 (0.5 μg/ml) treatment and the Il6 mRNA levels were checked using qRT-PCR (n = 3). (B) PEMs were incubated with control IgG or two PDPN antibodies (2 μg/ml) named anti-PDPN (B-11) or anti-PDPN (F-3) for 1 h followed by Pam3CSK4 (0.5 μg/ml) stimulation accompanied with BSA or UGRP1 (0.5 μg/ml) treatment for 6 h. Il6 mRNA levels were measured by qRT-PCR (n = 3). (C) HA-Vector or two HA-tagged PDPN clones suffixed with #1 or #2 were transfected into 293T cells respectively with FLAG-tagged UGRP1 clone. Immunoprecipitation and immunoblot were performed with the indicated antibodies. (D) GST protein and UGRP1-GST (2 μg) were incubated with PEMs’ lysate for 2 h followed by incubated with GST glutathione agarose for another 2 h. The samples were analysed by immunoblot. (E) Cas9-control and Cas9-Pdpn-deficient RAW264.7 cells were stimulated by Pam3CSK4 (0.5 μg/ml) with BSA or UGRP1 (0.5 μg/ml) for 6 h to measure Il6 mRNA levels by qRT-PCR (n = 3). (F and G) Cas9-control and Cas9-Pdpn-deficient RAW264.7 cells were treated with BSA or UGRP1 (0.5 μg/ml) for 6 h to measure Tlr2 mRNA levels by qRT-PCR (n = 3; F), or for 6 or 9 h to measure NLRP3, NOD2, TLR2, MyD88 and TLR4 expression by
eliminated this increased combination (Figure 5D,E). Simultaneously, increased phosphorylation of p65 was also eliminated with PDPN deficiency or RhoA inhibitor (Figure 5F,G). Then, we also observed overexpression of constitutively negative RhoA mutant N19 abrogated enhanced expression of IL-6 and TLR2 after UGRP1 treatment with or without Pam3CSK4 stimulation in RAW264.7 cells (Figure 5H and Figure S5A). Although PDPN was reported to interact with CLEC-2 (C-type-lectin-like-2) to inhibit inflammation in sepsis,27 extra CLEC-2 protein incubation had no effect on Il6 and Tnfa expression in Pam3CSK4-stimulated PEMs during our study (Figure S5B). Also, decreased expression of Clec2 did not regulate Il6 mRNA levels in Pam3CSK4-stimulated PEMs with or without UGRP1 treatment (Figure S5C,D), and similar expression of Tlr2 and Nos2 was observed in scrambled and Clec2 transfected PEMs (Figure S5E) indicating insignificant effect of CLEC-2–PDPN signalling in our studied inflammatory pathway. Together, we have demonstrated that UGRP1 activates RhoA to enhance the combination of IKKγ and IKKB, and our data have also elucidated a model linking the UGRP1–PDPN signalling to TLR2/NOD2-induced inflammation (Figure S5E).

2.6 | UGRP1 deficiency protects against S. pneumoniae-induced severe pneumococcal pneumonia

Given that extreme NF-κB activation plays an important role in sepsis and pneumonia, we investigated whether UGRP1 deficiency protected against severe pneumococcal pneumonia induced by S. pneumoniae. Extended survival time was observed in UGRP1 KO mice compared with their WT littermate controls following the intratracheal injection of S. pneumoniae (Figure 6A). In accord with the critical role of uncontrolled inflammatory response in pneumonia, significantly lower expression of IL-6 in BAL fluid of UGRP1 KO mice was observed (Figure 6B). Similarly, UGRP1 KO mice exhibited less Il6 (Figure 6C), Tnfa and Il1b (Figure S6A) mRNA levels in lungs, together with alleviative lung injuries (Figure 6D). In accordance with elevated TLR2, NOD2 and NLRP3 expression in PEMs after UGRP1 treatment, UGRP1 KO mice showed less Tlr2, Nos2 (Figure 6E) and Nlrp3 (Figure S6B) mRNA levels in lungs after S. pneumoniae infection. Pulmonary bacterial titres were also evaluated and UGRP1 KO mice displayed similar pulmonary bacterial loads compared with WT controls (Figure S6C), indicating that UGRP1 deficiency did not affect S. pneumoniae clearance. Moreover, Clodronate Liposome was used to clear resident AMs (Figure S6D), and decreased IL-6 was still observed in BAL fluid from UGRP1 KO mice (Figure S6E), suggesting that UGRP1 could also promote other cells inflammation in lung except for AMs. Meantime, we also observed that PDPN and F4/80 (a specific marker of mature macrophages) co-localised on the same cell in S. pneumoniae infected lung (Figure S6F). Then, flow cytometry was used to analyse the number of AMs and infiltrated monocytes in lung. As previous study reported,28 we used the markers CD11c<sup>high</sup> Siglec F<sub>high</sub> CD11b<sub>low</sub> to discriminate AMs, and we could see similar number of AMs between WT and UGRP1 KO mice without infection (Figure S6G,H). After S. pneumoniae infection, similar number of infiltrated monocytes (Ly-6C<sub>high</sub> CD11b<sub>high</sub>) and macrophages (Ly-6C<sub>high</sub> CD11b<sub>high</sub> F4/80<sub>high</sub>) between WT and UGRP1 KO mice was also observed (Figure S6I,J).

Next, we used anti-PDPN (B-II) antibody to interrupt interaction of UGRP1 and PDPN in WT mice, and extended survival time (Figure 6F) together with reduced IL-6 concentrations in BAL fluid (Figure 6G) was observed after S. pneumoniae infection. In addition, extra UGRP1 protein supplement in WT mice enhances IL-6 concentrations in BAL fluid after S. pneumoniae infection (Figure 6H). Anti-PDPN (B-II) antibody-injected mice also showed decreased mRNA levels of Il6 (Figure 6I), Tnfa and Il1b (Figure S6K) in lungs, accompanied by alleviative lung injuries (Figure 6J) compared with control IgG-injected
**FIGURE 5** UGRP1 activates RhoA to enhance the interaction of IKKγ and IKKβ. (A and B) PEMs (A) and Cas9-control or Cas9-Pdpn-deficient RAW264.7 cells (B) were treated with UGRP1 for indicated periods and the cell lysates were subjected to GST-Rhotekin-RBD pull-down assay to precipitate the activated RhoA. (C) Myc-RhoA, Myc-RhoA (V14, constitutively active mutant) or Myc-RhoA (N19, constitutively negative mutant) were transfected into 293T cells with FLAG-IKKγ and HA-IKKβ. Cell lysates were subjected to immunoprecipitation with anti-FLAG. (D) Cas9-control or Cas9-Pdpn-deficient RAW264.7 cells were treated with UGRP1 (0.5 μg/ml) for indicated periods and the cell lysates were subjected to immunoprecipitation with anti-IKKγ. (E) RAW264.7 cells were treated with DMSO control or RhoA inhibitor (CCG-1423, 20 μM) for 1 h followed by UGRP1 (0.5 μg/ml) stimulation for indicated periods and the cell lysates were subjected to immunoprecipitation with anti-IKKγ. (F) Cas9-control or Cas9-Pdpn-deficient RAW264.7 cells were treated with UGRP1 (0.5 μg/ml) for indicated periods and the cell lysates were subjected to detect phosphorylated (p-) p65. (G) RAW264.7 cells were treated with DMSO control or RhoA inhibitor (CCG-1423, 20 μM) for 1 h followed by UGRP1 (0.5 μg/ml) stimulation for indicated periods and the cell lysates were subjected to detect phosphorylated (p-) p65. (H) RAW264.7 cells stably overexpressing WT RhoA or RhoA N19 mutant were stimulated by Pam3CSK4 (0.5 μg/ml) with BSA or UGRP1 (0.5 μg/ml) for 9 h. IL-6 protein levels were measured by ELISA (n = 3, right pane) and overexpression of RhoA was checked by immunoblot (left panel). *p < .05, **p < .01 and ***p < .001, using two-way analysis of variance (ANOVA) with Holm–Sidak’s multiple comparisons test (H left panel). Data from at least three independent experiments (mean ± SD) or representative data (A–G, H right panel). Please also see Figure S5.

mice. In addition, anti-PDPN (B-11) antibody did not affect *S. pneumoniae* clearance (Figure S6L) and number of AMs (CD11chigh Siglec Fhigh CD11blow) and infiltrated monocytes (Ly-6C(F4/80(high)) and macrophages (Ly-6C(high) CD11b(high) F4/80(high)) (Figure S6M). AMs from B-11 antibody-treated mice showed decreased TLR2 expression (Figure S6N) and reduced Il6 mRNA levels after Pam3CSK4 stimulation (Figure 6K).

Then, RhoA activator Narciclasine was intratracheally injected into UGRP1 KO mice with *S. pneumoniae*
**FIGURE 6** UGRPI deficiency protects against *S. pneumoniae*-induced pneumonia. (A) WT and UGRPI KO mice were infected intratracheally with *S. pneumoniae* (4 x 10^5 CFU/mouse) and the survival time was assessed. (B–E) WT and UGRPI KO mice were infected intratracheally with *S. pneumoniae* (10^5 CFU/mouse). IL-6 in BAL (bronchoalveolar lavage) fluid was detected by ELISA at 1 day after inoculation (B, n = 5). Lungs were also harvested at 1 day post infection and IL6 (C, n = 6), Tlr2 and Nod2 (E, n = 4) mRNA levels were checked by qRT-PCR. Haematoxylin and eosin (H&E) staining of lung tissue was performed as well (D, scale bar: 20 μm). (F) WT mice pre-treated with control IgG or anti-PDPN (B-11) antibody (1 μg/mouse) were infected intratracheally with *S. pneumoniae* (4 x 10^5 CFU/mouse) to examine the survival time. (G) WT mice pre-treated with control IgG or anti-PDPN (B-11) antibody (1 μg/mouse) were infected intratracheally with *S. pneumoniae* (10^5 CFU/mouse). IL-6 in BAL fluid was detected by ELISA at 1 day after inoculation (n = 5). (H) WT mice treated with BSA or UGRPI (1 μg/mouse) for 1 day, following by infected intratracheally with *S. pneumoniae* (10^5 CFU/mouse). IL-6 in BAL fluid was detected by ELISA at 1 day after inoculation (n = 5). (I and J) WT mice pre-treated with control IgG or anti-PDPN (B-11) antibody (1 μg/mouse) were
infection and shortened survival time (Figure 6L) together with enhanced IL-6 concentrations in BAL fluid (Figure 6M) was observed compared with DMSO-injected UGRP1 KO controls. mRNA levels of Il6 (Figure 6N), Tnfa and Il1b (Figure S6O) also enhanced in lungs of Narciclasine-injected UGRP1 KO mice compared with DMSO-injected UGRP1 KO mice. Finally, we confirmed that extended survival time and reduced lung inflammation, which were resulted from UGRP1 deficiency, could be recovered by RhoA activation. These results suggest that UGRP1–PDPN signalling enhance S. pneumoniae-induced inflammation by activation of RhoA.

3 | DISCUSSION

In this study, we have showed that UGRP1 could enhance TLR2/4 and NOD2-induced signalling and pro-inflammatory cytokine production in macrophages. Additional UGRP1 treatment enhanced IL-6, TNFα and IL-1β production in macrophages with Pam3CSK4/ LPS/MDP/LTA stimulation or S. pneumoniae infection. In vivo, UGRP1 deficiency protected mice from S. pneumoniae-induced pneumonia, indicating that targeting UGRP1 could be used to protect the host from severe pneumonia.

As reported before, non-ciliated airway epithelial (club) cells of the trachea, bronchus and bronchioles showed abundant and specific expression of UGRP1.29 We also detected UGRP1 expression in different organs and macrophages, and UGRP1 was only detectable in lung. S. pneumoniae-infected AMs from UGRP1 KO mice showed decreased pro-inflammatory cytokine levels compared with those from WT mice. However, UGRP1 deficiency did not affect pro-inflammatory cytokine production in PEM and BMDM after S. pneumoniae infection, which indicated that the pro-inflammatory effect of UGRP1 might be restricted only to lung. The limited effect of UGRP1 was in accord with its distribution, which showed average 50–100 times higher in BAL fluid than in serum.21 In consideration of dilution of UGRP1 in BAL fluid preparation, macrophage might be confronted with more than 50–100 folds concentration of UGRP1 in lung than in blood. So, our study provides an interesting example on lung specific secretory protein regulates bacterial infection and inflammation locally, which will also trigger more interest in understanding the function of other lung secretory proteins in inflammation.

In our study, we also noticed that UGRP1-treated macrophages showed increased expression of NLRP3, which could take part in the formation of inflammasome and activate caspase-1 to catalyse maturation of IL-1β and IL-18.30,31 NLRP3 inflammasome could recognise RNA particles from the influenza virus and result in an inflammatory response which lead to the recruitment of immune cells, such as monocytes and neutrophils.32,33 The levels of lung injury were decreased in mechanically ventilated NLRP3 deficiency mice.34 It was also reported that NLRP3 inflammasome activity was closely associated with tumor progression in lung cancer.35 In consideration of multiple function of NLRP3 inflammasome, the role of UGRP1 should also be investigated extensively in lung inflammation, injury and cancer.

UGRP1 was verified to be a pro-inflammatory protein in our study, and mainly played the pro-inflammatory role in lung, where AMs are regulated routinely by UGRP1. UGRP1 deficiency results in the decreased TLR2 expression in AMs and reduced pro-inflammatory cytokines production after S. pneumoniae infection. Although UGRP1 promotes the inflammation in AMs, a considerable influence could negatively regulate AMs in the microenvironment of the airway. For example, SPA, which is abundant in the surface fluid of the epithelium, promotes an anti-inflammatory effect in the lungs by inhibiting the binding of TLR ligands to TLR2 and TLR4.36 Because of the positive and the negative regulation in lung, AMs are essential for steady state but are also ready to initiate an intense inflammatory response to some pathogen.

Since 2020, the coronavirus infectious disease 2019 (COVID-19), which is caused by a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread at the global scale.37 Higher levels of IL-6 and TNFα were observed in deceased patients infected with infected intratracheally with S. pneumoniae (10^5 CFU/mouse). Lungs were harvested at 1 day post infection and Il6 mRNA levels were checked by qRT-PCR (l, n = 4). H&E staining of lung tissue was performed as well (l, scale bar: 20 μm). (K) AMs from IgG or anti-PDPN (B-11) (1 μg/mouse) treated mice were stimulated with Pam3CSK4 for 6 h to check Il6 mRNA by qRT-PCR (n = 3). (L) WT and UGRP1 KO mice pre-treated with DMSO or RhoA activator (Narciclasine, 5 μg/mouse) were infected intratracheally with S. pneumoniae (4 × 10^5 CFU/mouse) to examine the survival time. (M and N) WT and UGRP1 KO mice pre-treated with DMSO or RhoA activator (Narciclasine, 5 μg/mouse) were infected intratracheally with S. pneumoniae (10^5 CFU/mouse). IL-6 in BAL fluid was detected at 1 day after inoculation by ELISA (K, n = 5). Lungs were also harvested at 1 day post infection and Il6 mRNA levels were checked by qRT-PCR (L, n = 4). *p < .05, **p < .01 and ***p < .001, using a two-tailed, unpaired Student's t-test (C, E and I), one-way analysis of variance (ANOVA) with Holm–Sidak's multiple comparisons test (M and N), two-way ANOVA with Holm–Sidak's multiple comparisons test (B, G, H and K) or log-rank (Mantel–Cox) test (A, F and L). Data from at least three independent experiments (mean ± SD) or representative data (D and J). Please also see Figure S6
COVID-19 compared with patients who had restored from the disease,\textsuperscript{38} and an uncontrolled cytokine response has also been observed in COVID-19 patients.\textsuperscript{39} As the RNA virus, SARS-CoV-2 could be recognised by RIG-I and activate IRF3 and NF-κB pathways, which promote the production of IFNβ, IL-6, TNFα and so on.\textsuperscript{40,41} So UGRP1, as a pro-inflammatory protein in lung, will attract more attention on its role in regulation of cytokine storm induced by COVID-19.

PDPN is a cell-surface mucin-type transmembrane glycoprotein.\textsuperscript{42} Previous studies have indicated that PDPN played a role in regulation of a variety of cellular signalling pathways, including proliferation, contractility, migration, chronic inflammation and cancer, which was dependent on binding of PDPN to its ligands.\textsuperscript{43} Binding of soluble CLEC-2 to PDPN restrains the inflammation induced by Th17.\textsuperscript{44} The interaction of PDPN with CCL21 in fibroblast-like reticular cells is relevant with the development of specialised T cells.\textsuperscript{45} In this work, we demonstrated that binding of UGRPI and PDPN-activated RhoA to enhance the interaction of IKKγ and IKKβ in macrophages. The increased interaction of IKKγ and IKKβ activated NF-κB to promote expression of TLR2, MyD88, NOD2 and NLRP3, which augmented the inflammation induced by \textit{S. pneumoniae} infection. So, we identified a new ligand which bond PDPN to regulate the inflammation in macrophage.

In summary, we have provided convinced evidence that the specific lung expressed secretion protein UGRPI binds macrophage cell surface receptor PDPN to modulate a novel inflammation pathway that enhances NF-κB phosphorylation in an TLR2/4-independent manner in response to \textit{S. pneumoniae} infection. Because of the extra-cellular location of UGRPI and the cell surface location of PDPN, specific antibodies could bind UGRPI or PDPN directly to regulate this signalling pathway. Because of the important role of UGRPI, PDPN and the pro-inflammatory cytokines including IL-6 and TNFα in inflammation, alternative site for drug design could be provided by this study.

\section{METHODS}

Following are the reagents or resources used in this study along with their respective sources.

| Reagent and resource | Source | Identifier |
|----------------------|--------|------------|
| Antibodies           |        |            |
| Rabbit anti-pp65     | Cell Signaling Technology | Cat# 8242 |
| Rabbit anti-IAβ      | Cell Signaling Technology | Cat# 4812 |
| Rabbit anti-pIKKαβ   | Cell Signaling Technology | Cat# 2697 |
| Rabbit anti-α-Tubulin| Cell Signaling Technology | Cat# 2125 |
| Rabbit anti-IKKβ     | Cell Signaling Technology | Cat# 8943 |
| Rabbit anti-RhoA     | Cell Signaling Technology | Cat# 2117 |
| Mouse anti-Myc       | Cell Signaling Technology | Cat# 2276 |
| Rabbit anti-Lamin B1 | Abcam  | Cat# ab229025 |
| Rabbit anti-MyD88    | Abcam  | Cat# ab219413 |
| Rabbit anti-MyD88    | Abcam  | Cat# ab20272 |
| Rabbit anti-UGRP1    | Abcam  | Cat# ab181853 |
| Rabbit anti-NLRP3    | Abcam  | Cat# ab263999 |
| Rabbit anti-IKKγ     | Abcam  | Cat# ab178872 |
| Rat anti-CD11b-APC   | Invitrogen | Cat# 17-0112-82 |
| Rat anti-F4/80-FITC  | Invitrogen | Cat# 11-4801-82 |
| Rat anti-CD8-APC     | Invitrogen | Cat# 17-0081-82 |
| Rat anti-B220-PE     | Invitrogen | Cat# 12-0452-82 |
| Rat anti-NOD2        | Invitrogen | Cat# 14-5858-82 |
| Rat anti-Ly-6C-PerCP-Cyanine5.5 & Armenian hamster anti-CD11c-APC | Invitrogen | Cat# 45-5932-80 |
| Rat anti-Siglec F-Alexa Fluor 488 | Invitrogen | Cat# 53-1702-82 |
| Mouse anti-HA        | Sigma–Aldrich | Cat# H3663 |
| Mouse anti-FLAG      | Sigma–Aldrich | Cat# F3165 |
| Mouse anti-PDPN (F-3) | Santa Cruz | Cat# sc-376962 |
| Mouse anti-PDPN (B-11) | Santa Cruz | Cat# sc-166906 |
| Mouse anti-GST       | YEASEN  | Cat# 30901E10 |
| Bacterial Streptococcus pneumoniae | ATCC | Cat# 6303 |
| Narciclasine          | MCE     | Cat# HY-16563 |
| Reagent and resource                      | Source | Identifier       |
|------------------------------------------|--------|------------------|
| CCG-1423                                 | MCE    | Cat# HY-13991    |
| CASIN                                    | MCE    | Cat# HY-12874    |
| 1A-116                                   | MCE    | Cat# HY-104064   |
| MBQ-167                                  | MCE    | Cat# HY-112842   |
| IRAK-1-4 Inhibitor I                    | MCE    | Cat# HY-13329    |
| Takinib                                  | MCE    | Cat# HY-103490   |
| LY2409881 trihydrochloride               | MCE    | Cat# HY-B0788A   |
| BAY II–7082                              | MCE    | Cat# HY-13453    |
| PDTC                                     | MCE    | Cat# HY-18738    |
| Pam3CSK4                                 | InvivoGen | Cat# tlr-pms   |
| LTA                                      | InvivoGen | Cat# tlr-slt   |
| MDP                                      | InvivoGen | Cat# tlr-mdp   |
| LPS                                      | Sigma–Aldrich | Cat# L3012 |
| GST                                      | Abcam  | Cat# ab81793     |
| CLEC-2                                   | Sino Biological | Cat# 50306-M01H |
| GST-UGRP1                                | Abcam  | Cat# ab239571    |
| CHX                                      | Millipore | Cat# 5.08739    |
| UGRP1                                    | Novoprotein | Cat# C190   |
| Mouse M-CSF                              | PeproTech | Cat# 315-02  |
| 3X FLAG Peptide                          | YEASEN | Cat# 20571ES11   |
| Protein G Agarose Resin                  | YEASEN | Cat# 36406ES08   |
| Anti-FLAG Affinity Gel                   | YEASEN | Cat# 20585ES01   |
| GSTSep Glutathione Agarose Resin         | YEASEN | Cat# 20508ES10   |
| Puromycin                                | YEASEN | Cat# 60210ES25   |
| Chemiluminescent HRP Substrate           | Millipore | Cat# WBKLS0500  |
| Lipofectamine RNAiMAX                    | Invitrogen | Cat# 13778030  |
| Lipofectamine 2000                      | Invitrogen | Cat# 11668030  |
| TRIzol                                   | Invitrogen | Cat# 15596018  |

| Reagent and resource                      | Source | Identifier       |
|------------------------------------------|--------|------------------|
| PrimeScript RT reagent kit               | Takara | Cat# RR047A     |
| TB Green Premix Ex Taq                   | Takara | Cat# RR420Q     |
| Critical Commercial Assays               |        |                 |
| IL-6 Mouse ELISA Kit                    | Invitrogen | Cat# 88-7064-22 |
| TNFα Mouse ELISA Kit                    | Invitrogen | Cat# 88-7324-22 |
| Cell Counting Kit (CCK-8)                | YEASEN | Cat# 40203ES60  |
| Active Rho Detection Kit                 | Cell Signaling Technology | Cat# 8820S   |
| Nucleoprotein Extraction Kit             | Sangon Biotech | Cat# C500009 |
| Cell lines                              |        |                 |
| HEK293T cells                            | ATCC   | Cat# ACS-4500   |
| THP-1                                    | ATCC   | Cat# TIB-202    |
| RAW264.7 macrophages                     | Laboratory of Hongyan Wang | N/A       |
| Organisms/strains                        |        |                 |
| Mouse: C57BL/6J                          | Shanghai Model Organisms | N/A      |
| Mouse: B6 Ugrp1^{-/-}                     | This paper | N/A          |
| Mouse: B6 Myd88^{-/-}                     | GemPharmatech | N/A       |
| Software and algorithms                  |        |                 |
| GraphPad Prism version 8.0               | GraphPad Software | https://www.graphpad.com/ |
| FlowJo v10                               | FlowJo | https://www.flowjo.com/solutions/flowjo |
| QuantStudio Real-Time PCR Software       | ABI    | N/A             |
| Recombinant DNA     | Cloning primers                                                                 | Cloning sites | Accession number |
|---------------------|---------------------------------------------------------------------------------|---------------|-----------------|
| pcDNA3.1-FLAG-UGRP1 | F: 5′-GGAATTCCGCCACCATGAAGCTGGTAACTATCTTC-3′                                  | XhoI          | NM_054023.5     |
|                     | R: 5′-TTGGGCGCCCTACTTGTGTCATCGTCTTTGTAGTCCA CCAAGTGTAGACCTCCT-3′               | NotI          |                 |
| pcDNA3.1-HA-PDPN    | F: 5′-GGAATTCCGCCACCATGAGCATGAGCTTGTA-3′                                      | EcoRI         | NM_00136367.2   |
|                     | R: 5′-GCTCTAGATTAAGCGTAATCTGGAACATCGTATGGGTCCTGACCTCCAGACC-3′                  | XbaI          |                 |
| pcDNA3.1-FLAG-IKKγ  | F: 5′-ACCGCTCGAGCCACCATGTATATCAGGTACTGCTGTGA-3′                              | XhoI          | NM_001136067.2  |
|                     | R: 5′-GCATGCGGCCGCTCTCTATGCACTCCATGACATG-3′                                   | NotI          |                 |
| pcDNA3.1-HA-IKKβ    | F: 5′-ACCGCTCGAGCCACCATGTATATCAGGTACTGCTGTGA-3′                              | XhoI          | NM_001159774.1  |
|                     | R: 5′-GCATGCGGCCGCTCTCTATGCACTCCATGACATG-3′                                   | NotI          |                 |
| pcDNA3.1-Myc-RhoA   | F: 5′-ACCGCTCGAGCCACCATGTATATCAGGTACTGCTGTGA-3′                              | XhoI          | NM_001313961.1  |
|                     | R: 5′-GCATGCGGCCGCTCTCTATGCACTCCATGACATG-3′                                   | NotI          |                 |
| pcDNA3.1-Myc-RhoAV14| F: 5′-ACCGCTCGAGCCACCATGTATATCAGGTACTGCTGTGA-3′                              | XhoI          | NM_001313961.1  |
|                     | R: 5′-GCATGCGGCCGCTCTCTATGCACTCCATGACATG-3′                                   | NotI          |                 |
| pcDNA3.1-Myc-RhON19 | F: 5′-GGAATTCCGCCACCATGAGCATGAGCTTGTA-3′                                    | EcoRI         | NM_001313961.1  |
|                     | R: 5′-GCATGCGGCCGCTCTCTATGCACTCCATGACATG-3′                                   | XbaI          |                 |
| pLVX-Myc-RhoA       | F: 5′-ACCGCTCGAGCCACCATGTATATCAGGTACTGCTGTGA-3′                              | XhoI          | NM_001313961.1  |
|                     | R: 5′-GCATGCGGCCGCTCTCTATGCACTCCATGACATG-3′                                   | NotI          |                 |
| pLVX-Myc-RhON19     | F: 5′-ACCGCTCGAGCCACCATGTATATCAGGTACTGCTGTGA-3′                              | XhoI          | NM_001313961.1  |
|                     | R: 5′-GCATGCGGCCGCTCTCTATGCACTCCATGACATG-3′                                   | NotI          |                 |

### 4.1 Mice

3.6 kbp genomic sequence including the whole UGRP1 gene was replaced by 2.3 kbp DNA fragment containing Neomycin cassette to generated UGRP1 KO mice, using a recombineering-based method (Shanghai Model Organism). Genotyping was performed with the following primers: forward, 5′-AGCATTCCTCTCAAACCCAACAG-3′ and reverse, 5′-GCATTCCTTGGTTTTTGTGTCA-3′. The mice were on a C57BL/6 background. MyD88-KO (B6/JGpt-Myd88em1Cd/Gpt) mice were purchased from Gempharmatech (Nanjing, China). All mice were raised under specific-pathogen-free conditions with approval of the National Institute for Viral Disease Control and Prevention. Mice were randomly distributed to different experimental groups with the same age (8–12 weeks), weight and sex. We determined the number of used mice with statistical methods and advice from related publications. All animal experiments were in agreement with the animal research related ethical regulations under the approval of the committee for humane treatment of animals at Shanghai Jiao Tong University School of Medicine.

### 4.2 Bacteria

*S. pneumoniae* used in this study was got from ATCC (#6303) and stored at −80°C in Todd-Hewitt Broth (THB, BD Biosciences) with 10% glycerol. Freshly grown colonies were obtained from 5% sheep blood agar plates (Yingxinbio) with overnight incubation and subsequently suspended in THB for 37°C incubation. Two hours later, bacteria got to logarithmic growth and were pelleted and resuspended in phosphate-buffered saline (PBS). Serial dilutions were then used to assess the bacterial concentrations.

### 4.3 S. pneumoniae infection and anti-PDPN (B-11) antibody or RhoA activator (Narciclasine) treatment

Under anaesthesia (chloral hydrate), WT or UGRP1 KO mice were intratracheally injected with 10⁵ or 4 × 10⁵ colony forming unit (CFU) of *S. pneumoniae* or PBS. Mice infected with 4 × 10⁵ CFU were observed for survival data. Mice infected with 10⁵ CFU were sacrificed at 1 day after infection. BAL fluid was collected and incubated on 5% sheep blood agar plates to determine the number of bacteria. BAL fluid was also used for IL-6 measurement and lungs were collected for H&E staining. Anti-PDPN (B11) antibody (1 μg/mouse) or RhoA activator (Narciclasine, 5 μg/mouse) were injected intratracheally into mice at the appointed time, followed by intratracheal inoculation of 10² or 4 × 10⁵ CFU of *S. pneumoniae*. Then, mice were monitored for survival time.
4.4  |  Cell culture

Cells were cultured at 37°C under 5% CO₂. PEMs were gathered from mice injected (intraperitoneal injection) with 3 ml 3% Brewer thioglycollate medium as previously described. RAW264.7 cells were gifts from H. Wang (SIBCB, CAS). PEMs, 293T and RAW264.7 cells were cultured in complete DMEM added with 10% (v/v) FBS, l-glutamine (2 mM), and penicillin–streptomycin (100 U/ml). THP-1 cells were cultured in complete RPMI 1640 medium and PMA 300 ng/ml, 12 h) was used to induce THP-1 to differentiate into macrophages. BMDMs were generated from bone marrow cells incubated with 30% L929-conditioned media for a week.

4.5  |  siRNA silence and qRT-PCR

Lipofectamine™ RNAiMAX Transfection Reagent (Invitrogen) was used to transfected siRNAs (Gene Pharma) into PEMs. Total RNA was extracted from cells with TRIzol (Invitrogen) and cDNA was generated with PrimeScript™ RT reagent Kit with gDNA Eraser (Takara). qRT-PCR was performed on a QuantStudio™ 6 Flex Real-Time PCR System (ABI) with TB Green® Premix Ex Taq™ (Takara). The relative mRNA levels, normalised to the 18sRNA, were calculated by the ∆∆Ct method. Sequences of all siRNA are listed in Table 1; all qRT-PCR primers are listed in Table 2, and primers for qRT-PCR used in ChIP assays are listed in Table 3.

4.6  |  Cas9-sgRNA was used to generate PDPN-deficient RAW264.7 cells

PDPN-deficient RAW264.7 cells were produced by CRISPR-associated protein-9 nuclease (Cas9)-mediated genome engineering as previously described. Briefly, PDPN-sgRNA was ligated to lentiCRISPR v2 plasmid (Addgene) with puromycin resistance. Lentivirus was harvested in the medium of 293T cells after transfected with lentiCRISPR-Pdpn-sgRNA, psPAX2 (addgene) and pMD2.G (addgene) for 36 h. RAW264.7 cells were infected with the lentivirus for 36 h, followed by cultured in complete DMEM with puromycin (5 μg/ml; YEASEN) for 48 h. The surviving cells were seeded into 96-well plates as single colony. Genome DNA from single colony was extracted and Sanger sequencing was used to analyse the single colony genotype. The PDPN-sgRNA sequences are shown below:

| Gene | Sequence |
|------|----------|
| Mouse Marco siRNA-1 | Sense: 5'-GGGUCAAAAAGGCGAAUCU-3' |
| Mouse Marco siRNA-2 | Antisense: 5'-AGAUUCGCCUUUUUGACCC-3' |
| Mouse Sdc1 siRNA-1 | Sense: 5'-GAACAAGACUUCACCUUUG-3' |
| Mouse Sdc1 siRNA-2 | Antisense: 5'-CAAAGGUGAAGCUUGUUC-3' |
| Mouse Pdpn siRNA-1 | Sense: 5'-GUUCUCCCAACACAUUGUAA-3' |
| Mouse Pdpn siRNA-2 | Antisense: 5'-UCAGAUGUGUGAGGGAGA-3' |
| Mouse Tlr2 siRNA-1 | Sense: 5'-GAUAAUCACCUACUUUGU-3' |
| Mouse Tlr2 siRNA-2 | Antisense: 5'-AACUAGAUGUGGAGUAUC-3' |
| Mouse Tlr4 siRNA-1 | Sense: 5'-GAUGAAAGGAAUCUGGAAA-3' |
| Mouse Tlr4 siRNA-2 | Antisense: 5'-UUUCCAGAUCUUCCAUAC-3' |
| Mouse Nod2 siRNA-1 | Sense: 5'-GCACAUUACCUUCCAGUG-3' |
| Mouse Nod2 siRNA-2 | Antisense: 5'-GGCACCUGAAGGAUGUGC-3' |
| Mouse Clec2 siRNA-1 | Sense: 5'-GGACUAUGUGAUGUGAGCA-3' |
| Mouse Clec2 siRNA-2 | Antisense: 5'-UGGUCCACUAAGUAUGUC-3' |

4.7  |  AMs isolation

AMs were isolated as previously reported. Briefly, the mouse was euthanised; then, the skin and muscles were removed to expose the trachea. A small incision was made below the larynx, and this incision was inserted by a blunted 20-G cannula (201483; Braun, Mersogenous, Germany) toward the lungs. Then, 0.5 ml PBS with 2% FBS were admitted into the lungs by syringe. The lungs were washed three times, and BAL fluid was collected. RBCs were removed by RBC lysis buffer (NH₄Cl), and the remaining cells were filtered through a 70 μm cell strainer. After centrifugation, AMs were collected.

4.8  |  Immunoprecipitation and immunoblot

Using Lipofectamine™ 2000 Transfection Reagent, 10 μg of control-vector plasmid or the suitable
TABLE 2 Primers for qRT-PCR used in this study

| Gene | Sequence |
|------|----------|
| **Mouse** | | |
| **Ugrp1** | F: 5′-ACTGCCCTTCTCATCAACCG-3′ |
| | R: 5′-CGATGCTGTCCACGAGATGTTGTC-3′ |
| **Marco** | F: 5′-ACAGAGCCGATTTTGGAACCAAG-3′ |
| | R: 5′-CAGCAGTGCAGTACCTGCC-3′ |
| **Tnfα** | F: 5′-AGTGACAAGCCTGTAGCCC-3′ |
| | R: 5′-GAGGTTGACTTTCTCCTGGTAT-3′ |
| **Il6** | F: 5′-TGTATGAACAACGATGATGCACTT-3′ |
| | R: 5′-ACTCTGGCTTTGTCTTTCTTGTTATCT-3′ |
| **Il1b** | F: 5′-GCAACTGTTCCTGAACTCAACT-3′ |
| | R: 5′-ATCTTTTGGGGTCCGTCAACT-3′ |
| **Il10** | F: 5′-CAGGGATCTTAGCTAACGGAAA-3′ |
| | R: 5′-GCTCAGTGAATAAATAGAATGGGAAC-3′ |
| **Tlr4** | F: 5′-ATGGCATGGCTTACACCACC-3′ |
| | R: 5′-GAGGCCAATTTTGTCTCCACA-3′ |
| **Tlr2** | F: 5′-GCAAACGCTGTTCTGCTCAG-3′ |
| | R: 5′-AGGCGTCTCCCTCTATTGTATT-3′ |
| **Nod2** | F: 5′-CAGGTCTCCGAGAGGGTACTG-3′ |
| | R: 5′-GCTACGGATGAGCCAAATGAAG-3′ |
| **Nlrp3** | F: 5′-ATTACCCGCCCGAGAAAGG-3′ |
| | R: 5′-TCGCAGCAAAGATCCACACAG-3′ |
| **Sdc1** | F: 5′-CTTTGTCACGGCAGACACCTT-3′ |
| | R: 5′-GACAGAGGTAAAAGCAGTCTCG-3′ |
| **Pdpn** | F: 5′-ACCGTGCCAGTGTTGTCTG-3′ |
| | R: 5′-AGCACCTTGTGTTTATTTGT-3′ |
| **Myd88** | F: 5′-TTACCCGCGCCAGAAAAAG-3′ |
| | R: 5′-TCGCAGCAAAGATCCACACAG-3′ |
| **Clec2** | F: 5′-AACATCCAAAGCCCCGGAAACAA-3′ |
| | R: 5′-GCCACAGTCCACACACAAC-3′ |
| **18s RNA** | F: 5′-AGTTCCAGCACATTTTGCGAG-3′ |
| | R: 5′-TCATCCTCCGTGAGTTCTCCA-3′ |

TABLE 3 Primers for qRT-PCR used in ChIP assays

| Site | Sequence |
|------|----------|
| **Nod2** site1 | F: 5′-CAGGGATCTTAGCTAACGGAAA-3′ |
| | R: 5′-GCTCAGTGAATAAATAGAATGGGAAC-3′ |
| **Nod2** site2 | F: 5′-CAGGTCTCCGAGAGGGTACTG-3′ |
| | R: 5′-GCTACGGATGAGCCAAATGAAG-3′ |
| **Tlr2** site1 | F: 5′-ATGGCATGGCTTACACCACC-3′ |
| | R: 5′-GAGGCCAATTTTGTCTCCACA-3′ |
| **Tlr2** site2 | F: 5′-ATGGCATGGCTTACACCACC-3′ |
| | R: 5′-GAGGCCAATTTTGTCTCCACA-3′ |
| **Negative control** | F: 5′-ATGGCATGGCTTACACCACC-3′ |
| | R: 5′-GAGGCCAATTTTGTCTCCACA-3′ |

expression plasmids was transfected into 293T cells (5 × 10⁶) cultured in 10 cm dishes. Thirty-six hours later after transfection, 1% NP-40 lysis buffer (20 mM Tris–HCl, 1% (v/v) NP-40, 137 mM NaCl, 10% (v/v) glycerol and 2 mM EDTA) was used to lyse 293T cells together with Protease Inhibitor Cocktail (Sigma–Aldrich), NaF and Na₃VO₄ followed by centrifugation. Anti-FLAG or indicated antibodies with Protein G Agarose Resin (YEASEN) were incubated with the collected supernates. Cold 1% NP-40 lysis buffer was used to wash the resins for three times. Then, the resins were suspended with 2 × loading buffer (4% SDS, 10% (v/v) 2-mercaptoethanol, 20% (v/v) glycerol, 0.004% bromophenol blue, 125 mM Tris–HCl) and boiled for 10 min. Subsequently, sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was operated to separate the samples and the samples were transferred to a polyvinylidene fluoride membrane which was then blocked by 5% BSA in tris-buffered saline and Tween 20 (TBST) at room temperature for 1 h. After incubated with primary antibodies and washed three times with TBST, the membrane was placed with corresponding horseradish peroxidase-labelled secondary antibodies and detected with Chemiluminescent HRP substrate (Millipore). Amersham Imager 600 (GE) was used to record the digital images. Endogenous co-immunoprecipitation experiments were operated with lysate of 1 × 10⁷ cells in 1 ml lysis buffer and the blot experiments were subsequently performed as described above.

4.9 Mass spectrometry analysis

To identify the receptor of UGRP1, purified FLAG-UGRP1 protein (5 μg) was incubated with the lysate of PEMs for 2 h at 4°C in the lysis buffer (20 mM Tris–HCl, 1% (v/v) NP-40, 137 mM NaCl, 10% (v/v) glycerol, 2 mM EDTA and protease inhibitor cocktail, pH 7.5), followed by incubated with the Anti-FLAG Affinity Gel (YEASEN) for 2 h at 4°C. After three washes and elution with the FLAG peptides, the proteins were used for the mass spectrometry analysis.

4.10 mRNA sequencing

PEMs were treated with BSA and UGRP1 respectively and RNA extract Kit (Qiagen, Germany) was used to extract total RNA according to the manufacturer's instruction. Sequencing libraries were established with 1 μg total RNA per sample, from which poly-T oligo-attached magnetic beads were used to purify mRNA. With an Illumina HiSeq platform, we sequenced the library
preparations and made 150 bp paired-end reads. Homo sapiens sequence (http://ftp://ftp.ensembl.org/pub/release-98/fasta/homo_sapiens/) with HISAT2 v2.0.5 was used to map the paired-end filtered reads. Each gene was calculated fragments per kilobase of transcript per million mapped fragments to normalise the read count. Finally, the different expression of the two groups was analysed with the DESeq R package (1.16.1).

### 4.11 Cell Counting Kit-8 assay

Cell Counting Kit-8 (CCK-8) assay was operated with the manufacturer’s instruction. Briefly, cells were seeded in a 96-well plate and incubated with indicated inhibitors and antibodies. Then, we added the same volume of CCK-8 solution to the plate which was subsequently incubated at 37°C (5% CO2) for 1 h. Thermo Scientific Multiskan Spectrum machine was used to measure the optical density at 450 nm.

### 4.12 GST pull down

UGRP1-GST (2 μg; Abcam) or GST protein (2 μg; YEASAN) were incubated with PEMS’ lysate at 4°C for 2 h in 200 μl pull-down buffer (20 mM Tris–HCl, 100 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 1 mM dithiothreitol, 1% (v/v) NP-40 pH 7.5), followed by incubated with GSTSep Glutathione Agarose Resin (YEASAN) for another 2 h. After washing three times, the resins were suspended in 2 × loading buffer and operated with SDS-PAGE.

### 4.13 RhoA activity assay

The active RhoA in PEMS and RAW264.7 cells was measured with Active Rho Detection Kit (CST) using the manufacturer’s instruction.

### 4.14 ChIP assay

PEMs were treated with BSA or UGRP1 (0.5 μg/ml) for 1 h and ChIP assay was operated with rabbit IgG and anti-p65 antibody. qRT-PCR was used to quantify the amount of TLR2 and NOD2 DNA fragments from the immunoprecipitated chromatin. Sequences of TLR2 and NOD2 fragments are listed in Table 3.

### 4.15 ELISA

ELISA kits (Invitrogen) were used to measure the concentrations of IL-6 and TNFα in mouse BAL fluid and cell supernate according to the manufacturer’s instruction.

### 4.16 Isolation of nucleic fractions

After treatment with 0.5 μg/ml UGRP1 for the indicated periods, the PEMS were harvested and washed with PBS. Then, buffer A (10 mM HEPES, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM dithiothreitol, 0.1% (v/v) NP-40 and protease inhibitor cocktail, pH 7.9) was used to lyse the cells. After centrifugation at 2152 g for 20 min at 4°C, supernate was discarded and the pellet was dissolved with cold buffer C (20 mM HEPES, 1.5 mM MgCl2, 0.42 M NaCl, 0.2 mM EDTA, 25% (v/v) glycerol, 0.5 mM dithiothreitol and protease inhibitor cocktail, pH 7.9). Nuclear protein was obtained with centrifugation at 8608 g for 1 min at 4°C to remove the insoluble material.

### 4.17 Flow cytometry

Single-cell suspension was obtained with a 70 μm nylon cell strainer. Then, the living cells were directly stained with the indicated antibodies in PBS containing 5% BSA for surface staining at 4°C in dark for 30 min. For intracellular staining, cells were initially fixed in 1% formaldehyde for 15 min, followed by PBS including 0.1% NP-40 treatment for 30 min. Then, cells were stained with the indicated antibodies in PBS containing 5% BSA. After washed with cold PBS, Calibur (BD Bioscience) was subsequently used to analyse the samples.

### 4.18 Statistics

All sample sizes were large enough to ensure proper statistical analysis. Data were represented as the means ± SD of at least three experiments. Statistical analyses were performed using GraphPad Prism 8 software (GraphPad Software, Inc.). Statistical significance was calculated using Student’s two-tailed unpaired t-test or analysis of variance with Holm–Sidak’s multiple comparisons test. The log-rank (Mantel–Cox) test was used for survival comparisons: ns, not significant (p > .05); *p < .05; **p < .01; ***p < .001.

### ACKNOWLEDGEMENTS

We thank Dr. Hongyan Wang for kindly providing us the RAW264.7 cells and Dr. Maocai Luo for useful advice. This
work was supported by National Natural Science Foundation (81800749 to X. Y. and 81670717 to B. H.), China Postdoctoral Science Foundation (No. 2018M630466 to L.H.), Innovative research team of high-level local universities in Shanghai (SHSMU-ZDCX20212501) and Natural Science Foundation of Shanghai (22ZR1436600).

CONFLICT OF INTEREST
The authors declare no conflict of interest.

ORCID
Lei Han https://orcid.org/0000-0002-5445-9568

REFERENCES
1. Subramanian K, Henriques-Normark B, Normark S. Emerging concepts in the pathogenesis of the Streptococcus pneumoniae: from nasopharyngeal colonizer to intracellular pathogen. *Cell Microbiol.* 2019;21:e13077.
2. Weiser JN, Ferreira DM, Paton JC. Streptococcus pneumoniae transmission, colonization and invasion. *Nat Rev Microbiol.* 2018;16:355-367.
3. Thaiss CA, Zmora N, Levy M, Elinav E. The microbiome and innate immunity. *Nature.* 2016;535:65-74.
4. Vance RE, Isberg RR, Portnoy DA. Patterns of pathogenesis: discrimination of pathogenic and nonpathogenic microbes by the innate immune system. *Cell Host Microbe.* 2009;6:10-21.
5. Opitz B, van Laak V, Eitel J, Suttorp N. Innate immune recognition in infectious and noninfectious diseases of the lung. *Am J Respir Crit Care Med.* 2010;181:1294-1309.
6. Chousterman BG, Swirski FK, Weber GF. Cytokine storm and sepsis disease pathogenesis. *Semin Immunopathol.* 2017;39:517-528.
7. Zhang Y, Lu Y, Ma L, et al. Activation of vascular endothelial growth factor receptor-3 in macrophages restrains TLR4-NF-kappaB signaling and protects against endotoxin shock. *Immunity.* 2014;40:501-514.
8. Ubil E, Caskey L, Holtzhausen A, Hunter D, Story C, Earp HS. Tumor-secreted Prost inhibits macrophage M1 polarization to reduce antitumor immune response. *J Clin Invest.* 2018;128:2356-2369.
9. Gill SE, Gharib SA, Bench EM, et al. Tissue inhibitor of metalloproteinases-3 moderates the proinflammatory status of macrophages. *Am J Respir Crit Care Biol.* 2013;49:768-777.
10. Reynolds SD, Reynolds PR, Pryhuber GS, Finder JD, Stripp BR. Secretoglobin superfamily protein SCGB3A2 deficiency potently decreases ovalbumin-induced allergic pulmonary inflammation. *Mediators Inflamm.* 2014;2014:216465.
11. Kido T, Yoneda M, Cai Y, Matsubara T, Ward JM, Kimura S. Secretoglobin superfamily protein SCGB3A2 deficiency potentiates ovalbumin-induced allergic pulmonary inflammation. *Eur J Endocrinol.* 2011;164:795-800.
12. Song HD, Liang J, Shi JY, et al. Functional SNPs in the SCGB3A2 promoter are associated with susceptibility to Graves’ disease. *Hum Mol Genet.* 2009;18:1156-1170.
13. Chiba Y, Kurotani R, Kusakabe T, et al. Uteroglobin-related protein 1 expression suppresses allergic airway inflammation in mice. *Am J Respir Crit Care Med.* 2006;173:958-964.
14. Kido T, Yoneda M, Cai Y, Matsubara T, Ward JM, Kimura S. Secretoglobin superfamily protein SCGB3A2 deficiency potentiates ovalbumin-induced allergic pulmonary inflammation. *Mediators Inflamm.* 2014;2014:216465.
15. Yoneda M, Xu L, Kajiyama H, et al. Secretoglobin superfamily protein SCGB3A2 alleviates house dust mite-induced allergic airway inflammation in mice. *Int Arch Allergy Immunol.* 2016;171:36-44.
16. Yokoyama S, Cai Y, Murata M, et al. A novel pathway of LPS uptake through syndecan-1 leading to pyroptotic cell death. *Elife.* 2018;7.
17. Yokoyama S, Nakayama S, Xu L, Pilon AL, Kimura S. Secretoglobin SA2 eliminates human cancer cells through pyroptosis. *Cell Death Discov.* 2021;7:12.
18. Porter D, Laht-Domenici J, Torres-Arzayus M, Chin L, Polyaek K. Expression of high in normal-1 (HIN-1) and uteroglobin related protein-1 (UGRP-1) in adult and developing tissues. *Mech Dev.* 2002;114:201-204.
19. Koppe U, Suttorp N, Opitz B. Recognition of Streptococcus pneumoniae by the innate immune system. *Cell Microbiol.* 2012;14:460-466.
20. Sato T, Akira S. Toll-like receptor signaling and its inducible proteins. *Microbiol Spectr.* 2016;4.
21. Van De Velde V, Courtens W, Bernard A. Development of a new sensitive ELISA for the determination of uteroglobin-related protein 1, a new potential biomarker. *Biomarkers.* 2010;15:619-624.
22. Bin LH, Nielson LD, Liu X, Mason RJ, Shu HB. Identification of uteroglobin-related protein 1 and macrophage scavenger receptor with collagenous structure as a lung-specific ligand-receptor pair. *J Immunol.* 2003;171:924-930.
23. Martin-Villar E, Megias D, Castel S, Yurrita MM, Vilaro S, Quintanilla M. Podoplanin binds ERM proteins to activate RhoA and promote epithelial-mesenchymal transition. *J Cell Sci.* 2006;119:4541-4553.
24. Navarro A, Perez RE, Rezaiekhaligh M, Mbamy SM, Ekekezie II. Tialpha/podoplanin is essential for capillary morphogenesis in lymphatic endothelial cells. *Am J Physiol Lung Cell Mol Physiol.* 2008;295:L543-551.
25. Navarro A, Perez RE, Rezaiekhaligh MH, Mbamy SM, Ekekezie II. Polarized migration of lymphatic endothelial cells is critically dependent on podoplanin regulation of Cdc42. *Am J Physiol Lung Cell Mol Physiol.* 2011;300:L32-42.
26. Kim JG, Choi KC, Hong CW, et al. Tyr42 phosphorylation of RhoA GTPase promotes tumorigenesis through nuclear factor (NF)-kappaB. *Free Radic Biol Med.* 2017;112:69-83.
27. Rayes J, Lax S, Wichaiyo S, et al. The podoplanin-CLEC-2 axis inhibits inflammation in sepsis. *Nat Commun.* 2017;8:2239.
28. Luo M, Lai W, He Z, Wu L. Development of an Optimized Culture System for Generating Mouse Alveolar Macrophage-like Cells. *J Immunol.* 2021;207:1683-1693.
29. Niimi T, Keck-Waggoner CL, Popescu NC, Zhou Y, Levitt RC, Kimura S. UGRP1, a uteroglobin/Clara cell secretory protein-related protein, is a novel lung-enriched downstream target gene for the T/EBP/NKX2.1 homeodomain transcription factor. *Mol Endocrinol.* 2001;15:2021-2036.
30. Nakanishi H, Kawashima Y, Kurima K, et al. NLRP3 mutation and cochlear autoinflammation cause syndromic and
nonsyndromic hearing loss DFNA34 responsive to anakinra therapy. Proc Natl Acad Sci USA. 2017;114:E7766-E7775.

31. Wolf AJ, Reyes CN, Liang W, et al. Hexokinase is an innate immune receptor for the detection of bacterial peptidoglycan. Cell. 2016;166:624-636.

32. Kuriakose T, Kanneganti TD. Regulation and functions of NLRP3 inflammasome during influenza virus infection. Mol Immunol. 2017;86:56-64.

33. Ren R, Wu S, Cai J, et al. The H7N9 influenza A virus infection results in lethal inflammation in the mammalian host via the NLRP3-caspase-1 inflammasome. Sci Rep. 2017;7:7625.

34. Dolinay T, Kim YS, Howrylak J, et al. Inflammasome-regulated cytokines are critical mediators of acute lung injury. Am J Respir Crit Care Med. 2012;185:1225-1234.

35. Wang Y, Kong H, Zeng X, et al. Activation of NLRP3 inflammasome enhances the proliferation and migration of A549 lung cancer cells. Oncol Rep. 2016;35:2053-2064.

36. Bain CC, MacDonald AS. The impact of the lung environment on macrophage development, activation and function: diversity in the face of adversity. Mucosal Immunol. 2022;15:223-234.

37. Giovannetti M, Angeletti S, Benvenuto D, Ciccozzi M. A doubt of multiple introduction of SARS-CoV-2 in Italy: a preliminary overview. J Med Virol. 2020;92:1634-1636.

38. Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020b;368:m1091.

39. Wu D, Yang XO. TH17 responses in cytokine storm of COVID-19: an emerging target of JAK2 inhibitor Fedratinib. J Microbiol Immunol Infect. 2020;53:368-370.

40. Chen K, Xiao F, Hu D, et al. SARS-CoV-2 nucleocapsid protein interacts with RIG-I and represses RIG-mediated IFN-beta production. Viruses. 2020a;12.

41. Copaescu A, Smibert O, Gibson A, Phillips EJ, Trubiano JA. The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection. J Allergy Clin Immunol. 2020;146:518-534. e511.

42. Astarita JL, Acton SE, Turley SJ. Podoplanin: emerging functions in development, the immune system, and cancer. Front Immunol. 2012;3:283.

43. Quintanilla M, Montero-Montero L, Renart J, Martin-Villar E. Podoplanin in Inflammation and Cancer. Int J Mol Sci. 2019;20.

44. Tuomela S, Rautio S, Ahlors H, et al. Comparative analysis of human and mouse transcriptomes of Th17 cell priming. Onco-target. 2016;7:13416-13428.

45. Fuertbauer E, Zaujec J, Uhrin P, et al. Thymic medullar conduits-associated podoplanin promotes natural regulatory T cells. Immunol Lett. 2013;154:31-41.

46. Sanjana NE, Shalem O, Zhang F. Improved vectors and genome-wide libraries for CRISPR screening. Nat Methods. 2014;11:783-784.

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Han L, Zhang F, Liu Yu, et al. Uterus globulin associated protein 1 (UGRP1) binds podoplanin (PDPN) to promote a novel inflammation pathway during Streptococcus pneumoniae infection. Clin Transl Med. 2022;12:e850. https://doi.org/10.1002/ctm2.850